DAWN (Day One Biopharmaceuticals) Net Margin %: -39.61% (As of Dec. 2025)


DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals Net Margin %?

Day One Biopharmaceuticals DAWN 12 Net Margin % is -39.61% as of Dec. 2025. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 947 Biotechnology companies, Day One Biopharmaceuticals ranks better than 52.38% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Day One Biopharmaceuticals's Net Income for the three months ended in Dec. 2025 was $-21.3 Mil. Day One Biopharmaceuticals's Revenue for the three months ended in Dec. 2025 was $53.7 Mil. Therefore, Day One Biopharmaceuticals's net margin for the quarter that ended in Dec. 2025 was -39.61%.

The historical rank and industry rank for Day One Biopharmaceuticals's Net Margin % or its related term are showing as below:

DAWN' s Net Margin % Range Over the Past 10 Years
Min: -72.81   Med: -70.33   Max: -67.85
Current: -67.85

DAWN's Net Margin % is ranked better than
52.38% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs DAWN: -67.85

Day One Biopharmaceuticals  (NAS:DAWN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Day One Biopharmaceuticals Net Margin % Related Terms

Day One Biopharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals Net Margin % Chart

Day One Biopharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -72.81 -67.85

Day One Biopharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -224.99 -117.02 -89.42 -49.57 -39.61

DAWN vs TYRA, DFTX, MLYS: Net Margin % Comparison

For the Biotechnology subindustry, Day One Biopharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Day One Biopharmaceuticals Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Day One Biopharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Day One Biopharmaceuticals's Net Margin % falls into.


DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Day One Biopharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-107.322/158.182
=-67.85 %

Day One Biopharmaceuticals's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-21.278/53.718
=-39.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -39.61% mean?
Day One Biopharmaceuticals (DAWN) has a Net Margin % of -39.61% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Day One Biopharmaceuticals and its competitors. According to the industry distribution chart, Day One Biopharmaceuticals ranks #451 out of 947 companies in the Biotechnology industry, placing it in the top 47.6%.
Is Day One Biopharmaceuticals' Net Margin % too high?
Day One Biopharmaceuticals' current Net Margin % is -39.61%. Based on the distribution chart, Day One Biopharmaceuticals ranks #451 out of 947 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Net Margin % compare to TYRA and DFTX?
According to the Biotechnology industry distribution chart, Day One Biopharmaceuticals ranks #451 out of 947 companies for Net Margin %. This puts Day One Biopharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Net Margin % is -39.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Net Margin % of -39.61%. The current Net Margin % is -39.61%. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Net Margin % is -39.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price